In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Toshiki Tsuboi, Keita Hattori, Takuji Ishimoto, Kentaro Imai, Tomohito Doke, Junichiro Hagita, Jumpei Ariyoshi, Kazuhiro Furuhashi, Noritoshi Kato, Yasuhiko Ito, Yukiko Kamiya, Hiroyuki Asanuma, Shoichi Maruyama
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	Molecular Therapy: Nucleic Acids
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253125000514
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01)

WCN24-1446 The Role of Long Non-Coding RNAs in the Progression of Renal Fibrosis
by: TAKUJI ISHIMOTO, et al.
Published: (2024-04-01)

Pharmacokinetics of antisense oligonucleotide drugs
by: M. R. Khaitov, et al.
Published: (2013-04-01)

Tofersen and other antisense oligonucleotides in ALS
by: Albert Ludolph, et al.
Published: (2025-01-01)

Antisense oligonucleotides targeting IRF4 alleviate psoriasis
by: Yanxia Yu, et al.
Published: (2025-07-01)

Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01)

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
by: Daisuke Ito, et al.
Published: (2024-12-01)

Halloysite clay nanotubes as platforms for loading of aptamers and antisense oligonucleotides
by: Maria Rita Caruso, et al.
Published: (2025-03-01)

Antisense oligonucleotide targeting nicotinamide N-methyltransferase exhibits antitumor effects
by: Tomoaki Hara, et al.
Published: (2025-06-01)

Programmable Single-Stranded Circular Antisense Oligonucleotides for Multitarget Gene Therapy
by: Yufan Pan, et al.
Published: (2025-07-01)

Identifying antisense oligonucleotides for targeted inhibition of insulin receptor isoform A
by: Christopher A. Galifi, et al.
Published: (2025-04-01)

Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01)

SNA-modified antisense oligonucleotides: A new pathway for renal targeting?
by: Bernhard Dumoulin, et al.
Published: (2025-03-01)

Targeting FANCM using the antisense oligonucleotides to treat the ALT-positive cancers
by: Shakir Naji, et al.
Published: (2025-06-01)

Prediction of retention time in larger antisense oligonucleotide datasets using machine learning
by: Manal Rahal, et al.
Published: (2025-09-01)

Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides
by: Shahnaz Begum, et al.
Published: (2025-04-01)

Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference
by: Olga Golounina, et al.
Published: (2025-01-01)

Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals
by: K.-H. Altmann, et al.
Published: (1999-05-01)

ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS
by: O. I. Afanasieva, et al.
Published: (2018-09-01)

Anti-TNF-α antisense-oligonucleotide-conjugated PLG nanoparticles protect transplanted islets
by: Elizabeth J. Bealer, et al.
Published: (2025-06-01)

Multispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides
by: Kohshi Kusumoto, et al.
Published: (2025-01-01)

SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
by: Yanzhi Wang, et al.
Published: (2025-06-01)

Antisense Oligonucleotide-Capped Gold Nanoparticles as a Potential Strategy for Tackling Antimicrobial Resistance
by: Cesar Rodolfo Garza-Cardenas, et al.
Published: (2025-03-01)

Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment
by: Ana Cubillo Alvarez, et al.
Published: (2025-03-01)

Analysis of Use of Antisense Oligonucleotides for Prevention and Treatment of Hazardous and Extremely Hazardous Viral Infectious Diseases
by: A. A. Petrov, et al.
Published: (2020-05-01)

Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides
by: Anthony J Hinrich, et al.
Published: (2016-02-01)

Antisense Oligonucleotides Directed Against a Human Endogenous Retrovirus for Treatment of Amyotrophic Lateral Sclerosis
by: Kevon Sampson, M.S., et al.
Published: (2024-07-01)

Superior Silencing by 2′,4′-BNANC-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors
by: Tsuyoshi Yamamoto, et al.
Published: (2012-01-01)

Antisense oligonucleotides targeting the SARS-CoV-2 nucleocapsid gene decrease viral titers in hamsters
by: Christopher Fitzpatrick, et al.
Published: (2025-09-01)

RNA G‑Quadruplex Reprogramming with Guanine-Rich Antisense Oligonucleotides Inhibits Monoamine Oxidase B’s Translation
by: Marc-Antoine Turcotte, et al.
Published: (2025-03-01)

An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
by: Pratibha Thakur, et al.
Published: (2025-05-01)

SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotides
by: Andrea Loreto, et al.
Published: (2025-09-01)

Locked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF
by: Jinhe Li, et al.
Published: (2025-08-01)

In Vitro Structure–Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases
by: Jelena Lovrić, et al.
Published: (2025-06-01)

When HERG-caused LQT2 encounters antisense oligonucleotide: is exon 6 skipping therapy plausible?
by: Zequn Zheng, et al.
Published: (2025-03-01)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment.
by: Palittiya Sintusek, et al.
Published: (2016-01-01)

Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease
by: Sergio Adrian Ocampo-Ortega, et al.
Published: (2024-12-01)

Antisense oligonucleotide therapy for patients with Friedreich’s ataxia carrying the c.165+5G>C splicing mutation
by: Pouiré Yameogo, et al.
Published: (2025-09-01)

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease
by: Lan Weiss, et al.
Published: (2025-04-01)

Systematic analysis of genetic and phenotypic characteristics reveals antisense oligonucleotide therapy potential for one-third of neurodevelopmental disorders
by: Kim N. Wijnant, et al.
Published: (2025-05-01)